<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186277</url>
  </required_header>
  <id_info>
    <org_study_id>BLDR0001</org_study_id>
    <secondary_id>BLDR0001</secondary_id>
    <nct_id>NCT00186277</nct_id>
  </id_info>
  <brief_title>Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer</brief_title>
  <official_title>Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in
      bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test the combination of oxaliplatin chemotherapy in combination with taxotere chemotherapy
      in patients with advanced bladder cancer who have failed one prior chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of the this combination in patients with recurrent metastatic bladder cancer.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Calculated per patient</description>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere</intervention_name>
    <description>Calculated per patient</description>
    <other_name>Docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Patient Population Type: Advanced Muscle Invasive Bladder Cancer

          -  Prior Therapy: One prior therapy for advanced disease

          -  Disease: Measurable disease

          -  ECOG Performance: 0,1

          -  Indication: Histologically Proven Carcinoma of the bladder

          -  For female patient of childbearing potential, neither pregnant nor breastfeeding, and
             under active contraception

          -  Allergies: No known allergy to one of the study drugs

          -  Patient Status:

          -  No CNS metastases

          -  No peripheral neuropathy &gt; grade1

          -  No other serious concomitant illness

          -  Fully recovered from any prior therapy

          -  Informed Consent: Patient and doctor have signed informed consent

          -  Lower Age Limit: Lower age limit &gt;18

          -  Upper Age Limit: Upper Age Limit &lt;70

          -  ANC: ANC &gt;1500/mm3 or WBC &gt; 3000/mm3

          -  Platelets: Platelets &gt;100,000/mm3

          -  Creatinine: Creatinine &lt;1.8mg/dL

          -  Bilirubin: Bilirubin &lt;=2.0 x ULN

          -  SGPT: SGPT (ALT) &lt;=1.5 x ULN (&lt;4xULN if liver metastases present)

          -  RBC: Hemoglobin &gt; 9.0g/dL

          -  Cardiovascular: No active congestive heart failure, no uncontrolled angina, no
             myocardial infarction within the past 6 months

          -  Patients with metastatic cancer of the urothelial tract (TCC, Adenocarcinoma)

          -  No prior exposure to Oxaliplatin

          -  No cytotoxics or radiation 4 weeks prior to enrolling on protocol

          -  PT/PTT normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Sandy Srinivas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>March 28, 2011</last_update_submitted>
  <last_update_submitted_qc>March 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sandy Srinivas</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

